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There is increasing evidence that non-enzymatic post-translational protein modifications might play
key roles in various diseases. These protein modifications can be caused by free radicals generated
during oxidative stress or by their products generated during lipid peroxidation. 4-Hydroxynonenal
(HNE), a major biomarker of oxidative stress and lipid peroxidation, has been recognized as important
molecule in pathology as well as in physiology of living organisms. Therefore, its detection and
quantification can be considered as valuable tool for evaluating various pathophysiological conditions.
The HNE-protein adduct ELISA is a method to detect HNE bound to proteins, which is considered as
the most likely form of HNE occurrence in living systems. Since the earlier described ELISA has been
validated for cell lysates and the antibody used for detection of HNE-protein adducts is non-
commercial, the aim of this work was to adapt the ELISA to a commercial antibody and to apply it in
the analysis of human plasma samples.
After modification and validation of the protocol for both antibodies, samples of two groups were
analyzed: apparently healthy obese (n¼62) and non-obese controls (n¼15). Although the detected
absolute values of HNE–protein adducts were different, depending on the antibody used, both ELISA
methods showed significantly higher values of HNE–protein adducts in the obese group.
& 2013 The Authors. Published by Elsevier B.V. All rights reserved.Introduction
In recent decades evidence has arisen that not only genetic but
also epigenetic, mostly stress-related, mechanisms are involved in
pathophysiology of aging and age-associated disorders. Among
these mechanisms are non-enzymatic post-translational protein
modifications which may alter structural and biological properties
of proteins in living organisms. These alterations might be recog-
nized as key events in certain diseases like degenerative diseasesPublished by Elsevier B.V. All righ
r the terms of the Creative
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lly to this workassociated with protein storage. Such modifications of proteins are
often influenced by their environment, their structural features, by
protein folding states, as well as by free radicals generated in their
vicinity. Abundant generation of reactive oxygen species (ROS)
causes oxidative stress, which represents an imbalance between
production of ROS and their elimination through antioxidative
defense mechanisms [1]. ROS can attack all cellular macromolecules
of which lipids are particularly susceptible. Since cholesterol esters,
phospholipids, and triglycerides all contain polyunsaturated fatty
acids (PUFAs) they are subject to free radical attack. Lipid peroxida-
tion is marked by the breakdown of PUFAs yielding oxidation
products such as reactive aldehydes of 3–9 carbons length of which
4-hydroxynonenal (HNE), malondialdehyde (MDA) and acrolein
(ACR) are the most studied ones. These bioactive compounds can
react with all major biomolecules of the cell, thus changing their
structure and function and consequently influencing cellular phy-
siology and pathophysiology.
Compared to free radicals, aldehydic products such as MDA
and HNE are relatively stable and are able to roam freely and
attack molecules, e.g. DNA, proteins, lipids far from the site of
their origin. Amongst others, these aldehydic fragments may
modify proteins and alter protein function, but are also consid-
ered as cytotoxic second messengers of oxidative stress whichts reserved.
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[2,3]. Therefore, developing new methods for detection and
quantification of these compounds in all kinds of biological
samples, as well as improving the current ones, is of the utmost
importance in the field of research related to oxidative stress.
4-Hydroxynonenal (HNE), a well known biomarker of oxida-
tive stress and lipid peroxidation, is derived from o-6 PUFAs such
as arachidonic acid and linoleic acid and has been recognized as
important molecule in pathology, as well as in physiology of
living organisms [3–5]. Intracellular HNE reacts rapidly with thiol
groups of glutathione and cysteine, with e-amino groups of lysine,
and with histidine residues of proteins [6,7]. Increased concen-
trations of HNE–modified proteins have been detected in various
diseases, among them cancer, atherosclerosis, neurodegenerative
disorders, ischemia, inflammation, diabetes, autoimmune dis-
eases, bone diseases and aging [8–13].
As already mentioned, HNE can bind to proteins, forming
relatively stable adducts, which are considered as the most likely
form of its occurrence in living systems. We have previously
reported that these HNE–protein adducts can be measured and
quantified by an ELISA method using a mouse monoclonal anti-
body that specifically recognizes the HNE-histidine epitope [14].
Taking into consideration that ELISA methods require only micro-
grams of protein, they are suitable for clinical trials where only
small amounts of material is available. Because it is becoming of
increasing interest to evaluate the level of HNE-protein adducts in
different human pathologies as well as in healthy human subjects,
our aim was to establish a method that can be widely applied. Up
to now, the only reliable and convenient method was the ELISA
established for cell lysates by Borovic et al. [14]. To allow other
researchers that are not able to use the non-commercial antibody
to measure protein adducts of HNE by the ELISA used there, we
selected one of the few available monoclonal antibodies against
adducts of HNE. By comparing these two antibodies, it allows to
compare results obtained with the commercial antibody in the
future with those obtained with the non-commercial antibody.
On the other hand, the existing HNE–protein adduct ELISA was
originally developed and validated for cell lysates and since the
primary antibody used is non-commercial, we wanted to accom-
plish two goals: (a) to validate and if necessary modify the current
protocol to be applicable for testing plasma/serum samples and
(b) to compare the original non-commercial antibody (nc-Ab)
with a commercial antibody (c-Ab), thus developing an ELISA
method that differs only in the primary antibody used and that
could be applied in all research laboratories related to lipid
peroxidation and oxidative stress research. The here presented
method is applicable to serum and plasma samples, when using a
non-commercial as well as a commercially available antibody.Materials and methods
Chemicals of best analytical grade available were purchased
from Sigma-Aldrich (Taufkirchen, Germany) or Carl Roth (Karls-
ruhe, Germany), unless otherwise stated. Distilled water was used
throughout for preparation of all solutions.
Primary antibodies used throughout were: commercial Ab (c-Ab):
mouse monoclonal anti-4-Hydroxynonenal antibody (clone HNEJ-2;
Abcam, Cambridge, UK); and non-commercial Ab (nc-Ab): genuine
monoclonal mouse anti-HNE-His antibody in cell culture super-
natant (clone HNE 1g4; produced and provided by Dr. Georg Waeg,
Karl-Franzen’s University in Graz, Institute of Molecular Biosciences,
Austria). Secondary antibody was EnVisionþ System-HRP Labeled
Polymer anti-mouse (Dako, Denmark).HNE–BSA standard preparation
HNE-dimethylacetal (Enzo Life Sciences) solution was dried under
nitrogen flow and dissolved in 1 mM HCl at room temperature (RT)
overnight. The concentration of this solution was determined by
measuring the absorbance at 223 nm (e¼13,750M1 cm1 [15])
with water as blank (Shimadzu, UV160-A). Afterwards, the solution
was diluted to 1 mM with water.
For preparation of HNE–BSA standards, fatty acid free BSA was
diluted in PBS to a protein concentration of 10 mg/ml. The zero
standards consisted of fatty acid free BSA (no HNE). The highest
standard concentration was prepared by adding different amounts
of 1 mM HNE to fatty acid free BSA giving concentrations of
250 pmol/mg (ELISA with nc-Ab) and 5000 pmol/mg (ELISA with
c-Ab). Prepared stock solutions were incubated for 3 h at 37 1C or
overnight at 4 1C, to achieve complete binding of HNE to BSA, and
stored at 20 1C until analysis.
ELISA procedure
This ELISA protocol was adapted from Borovic et al. [14].
Standards were prepared from stock solutions (stored at 20 1C)
in concentrations ranging from 0 to 250 pmol/mg (ELISA with nc-
Ab) or from 0 to 5000 pmol/mg (ELISA with c-Ab), respectively, by
mixing varying proportions of HNE-BSA and fatty acid free BSA
while the total protein concentration remained 10 mg/ml. Standards
and diluted plasma/serum samples (10 mg/ml), respectively, were
diluted 10-fold in 0.05 M carbonate binding buffer (pH 9.6; 0.015 M
sodium carbonate, 0.035 M sodium bicarbonate). 100 ml of this
mixture were transferred into wells of an ELISA plate (Nunc Immuno
Maxisorp, Thermo Scientific) for triplicate analysis. Proteins were
adsorbed to wells of the plate overnight at 4 1C. The following day,
the plate was washed once with PBS (300 ml). Freshly prepared
blocking solution (5% fat free dry milk in carbonate binding buffer)
was transferred into wells and the plate was blocked for 2.5 h at RT
followed by one washing step (0.1% Tween 20 in PBS). Primary
antibody solution in 1% BSA in PBS (nc-Ab 1:100; c-Ab 1:500) was
incubated for 2 h at 37 1C. To eliminate sample background values
one well of each sample was incubated with 1% BSA in PBS (without
primary antibody). After washing the plate seven times, it was
incubated for 30 min with peroxidase blocking solution (3% H2O2 in
PBS) at RT. Then it was again washed seven times. 100 ml of the goat
anti-mouse secondary antibody solution in 1% BSA in PBS (1:100;
Dako) were transferred into the wells and incubated for 1 h at RT,
followed by a washing step (seven times). Freshly prepared TMB
substrate solution (0.05 mg/ml) was transferred into the wells and
after 30 min at 37 1C the reaction was stopped by adding 50 ml of
stopping solution (2 M sulfuric acid). Absorption was read at 450 nm
with the reference filter set to 620 nm. All analyses were performed
in triplicate or quadruplicate and the amounts of HNE–protein
adducts measured by the ELISA are expressed as pmol HNE/mg of
proteins.
Analysis of samples
Sixty-two serum samples of morbidly obese candidates for
surgical intervention were obtained from the Department of
Surgery, University Hospital Mannheim (Germany) on the day
before laparoscopic Roux-en-Y gastric bypass surgery. Oxidative
stress markers HNE and MDA were compared with those in
Na-heparin plasma obtained from 15 healthy controls which were
kind gifts from Dr. Ina Bergheim from the University of Hohen-
heim (Germany). The study was approved by the Ethics Commit-
tees of the Institutions and informed consent was obtained from
all participants. Blood samples were collected into appropriate
tubes and serum or plasma, respectively, was separated from
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respectively.
Sample preparation
Total protein concentration of standards and plasma/serum,
respectively was determined by the BioRad assay according to
Bradford [16].
HNE-ELISA
Plasma and serum samples where diluted to a protein con-
centration of 10 mg/ml with PBS for ELISA analysis. HNE-protein
adducts were analyzed by the ELISA as described above.
HPLC-analysis of malondialdehyde (MDA)
Malondialdehyde (MDA) in serum of obese patients and
plasma of normal weight controls was determined by HPLC-
analysis after derivatization with thiobarbituric acid (TBA) as
describe by Wong et al. [17]. Quantification is done based on
the area of the peaks compared to standards and expressed in mM.
Evaluation of differences observed in ELISA sensitivity and specificity
Capping experiment
BSA was treated with diethyl pyrocarbonate (DEPC) to block
the amino acid Histidine. Histidine derivatization: 0.1% DEPC, a0.14
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Fig. 1. ELISA standard curves for both ELISA methods. (A) Typical ELISA standard
curve using non-commercial antibody (nc-Ab). Standards were measured in
quadruplicate in concentrations ranging from 0 to 250 pmol/mg. (B) Typical ELISA
standard curve using commercial antibody (c-Ab). Standards were measured in
quadruplicate in concentrations ranging from 0 to 2500 pmol/mg. Both curves
were repeated multiple times.histidine-specific alkylating reagent was added to BSA (fatty acid
free; 10 mg/ml) resuspended in 0.1 M sodium phosphate (pH 6.5)
for 10 min at RT. The efficiency of histidine modification following
DEPC treatment was proved by a shift in absorbance at 242 nm
[18].
Dot Blots of capping experiments
Previously prepared samples (10 mg/ml) were diluted 20-fold
and 100 ml were spotted onto nitrocellulose membrane (Amer-
sham). The membrane was incubated in blocking solution (2%
nonfat milk powder in PBS) for 1 h at RT and subsequently
incubated overnight with primary antibodies (nc-Ab and c-Ab)
diluted 1:100. After washing, the blots were incubated with 3%
H2O2 to block endogenous peroxidases. Following another wash-
ing step, they were incubated with the secondary antibody for
1 h. Immune complexes were visualized using 3, 30-diaminoben-
zidine tetrahydrochloride (Dako) staining and scanned for quan-
tification of signals. Blanks were included in all experiments in
which the antibody was omitted and replaced by control diluent
(1% BSA in PBS).
Immunoblot analysis (western blot)
Prior to detection of nc-Ab and c-Ab binding, respectively,
to HNE-protein adducts in HNE-treated BSA standards (120,
1250 pmol/mg) and human plasma, the protein concentration was
measured with the Bradford assay. Samples were prepared with
Laemmli buffer (v/v) and heated at 95 1C for 10 min. Twenty
(for nc-Ab) or 30 mg (for c-Ab) of protein per lane in Laemmli
buffer were subjected to SDS-polyacrylamide gel electrophoresis
(SDS-PAGE, 10%). After electrophoresis the separated proteins were140
Comparison of Recovery for both ELISA
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Fig. 2. Comparison of recovery for both ELISA methods. Recovery of HNE–BSA
standards in plasma samples was determined for both ELISA methods (c-Ab and
nc-Ab). Plasma and serum samples were spiked with different concentrations of
HNE–BSA and analyzed in triplicate. Recovery is expressed in percent. Columns
are mean7S.D, n¼3.
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nonfat milk powder/TBS-Tween (50 mM Tris-base, pH 7.5, 200 mM
sodium chloride, 0.05% Tween 20) overnight at 4 1C under constant
agitation, followed by incubation with primary antibodies (nc-Ab:
1:100; c-Ab: 1:250) for 2 h at RT. After being washed three times,
the blots were incubated with secondary antibody (1:100) for 2 h at
RT. Blots were washed and exposed to the substrate ECL Reagent
(Calbiochem). Visualization of bound secondary antibody was
detected by enhanced chemiluminescence.Statistical analysis
Basic descriptive statistics means, standard deviation (S.D.)
were used. Means were compared using Student’s t-test.Results
Comparison of ELISA methods
Both methods showed linear standard curves in the range in
which serum and plasma samples were expected (Fig.1).
Recovery
For determining the recovery of HNE-modified BSA with the nc-
Ab, plasma and serum samples were spiked with standards by
adding one volume of standard to one volume of sample, resulting
in additional concentrations of 250, 62.5, and 7.8 pmol/mg, respec-
tively. The mean recovery for the nc-Ab was measured to be
between 100.073.3% (250 pmol/mg), 96.5714.4% (62.5 pmol/mg)
and 99.274.5% (7.8 pmol/mg). Mean recovery was 98.676.1%
(Fig. 2). The recovery of the ELISA applying the c-Ab was determined
by spiking samples with standard by adding one volume of standard
to nine volumes of sample, resulting in additional concentrations
of 250, 100, and 0 pmol/mg, respectively. The mean recovery
was calculated to be between 108.6718.5% (250 pmol/mg) andLimits of Detection for
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Fig. 3. Limits of detection for both ELISA methods. Concentration limits for HNE-ELISA. Sho
limit of quantification (LOQ) for the nc-AB (A) and c-Ab (B). Data represent mean7S.D98.1717.4% (100 pmol/mg). Mean recovery was 103.3718.4%
(Fig. 2).Limit of detection (LOD), practical quantitation limit (PQL), and limit
of quantification (LOQ)
Limit of detection (LOD), practical quantitation limit (PQL), and
limit of quantification (LOQ) were calculated as described pre-
viously [19,20]. The LOD for the nc-Ab is 9.772.5 pmol/mg, the
PQL is 17.275.0 pmol/mg, and the LOQ is 24.677.4 pmol/mg.
For the c-Ab, the limit of detection (LOD) is 405.4748.0 pmol/mg,
the practical quantitation limit (PQL) is 657.2786.0 pmol/mg,
and the limit of quantification (LOQ) is 909.07157.6 pmol/mg
(Fig.3).Inter-day variance and inter-assay variance
As shown in Table 1, lower inter-day and inter-assay variations
were calculated for the ELISA with nc-Ab compared to the method
with the c-Ab, respectively. Regardless of the antibody used
for either variance the variation was in the range between 13%
and 22%.HNE-protein adducts in samples of obese patients and normal weight
controls
Since both ELISA tests worked satisfactorily using HNE-
modified BSA standards, human blood was employed to perform
an analysis of HNE-modified proteins. HNE-protein adduct con-
centrations in obese patient (serum, n¼62) and normal weight
control (plasma, n¼15) samples were measured by both ELISA
methods. Fig. 4 shows that obese patients have significantly
elevated levels of HNE–protein adducts (nc-Ab: po0.001; c-Ab:
po0.05).1200
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Fig. 5 demonstrates the correlation between the measured
HNE-protein adduct concentrations detected by both ELISA meth-
ods (r¼0.305, po0.01) using the 77 samples of obese (n¼62) and
normal weight persons (n¼15) (Fig. 5).
Correlation with MDA
HNE–protein adduct concentrations of obese and control sam-
ples determined by each of the ELISA methods were plotted against
MDA concentrations of the same samples. The HNE-protein adducts
in plasma/serum determined using the nc-Ab correlate highly
significantly with MDA (r¼0.779, po0.001), HNE–protein adducts
in plasma/serum determined using the c-Ab also correlate highly
significantly with MDA (r¼0.456, po0.001, see Fig. 6).
Dot blot
Interestingly, both ELISAs show essentially the same results
in correlation with the independent parameter MDA. It is remark-
able that the absolute detected levels differ approximately
some 40-fold. This is most likely due to the specificity of
the antibody. Therefore, the specificity of antibody binding to
HNE–His epitopes was tested. Since it is known that HNE binds to
Cys, His, and Lys, and as both antibodies are declared to beTable 1
Inter-day and inter-assay variation.
Inter-day variation (%) Inter-assay variation (%)
nc-Ab 13.6 13.8
c-Ab 22.6 16.6
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Fig. 4. HNE–protein adducts in samples. Concentration of HNE–protein adducts in samples of obese patients (n¼62) and normal weight controls (n¼15). (A) ELISA using nc-
Ab was applied to 62 serum samples of obese persons and 15 plasma samples of non-obese subjects. Obese subjects show significantly higher levels of HNE–protein
adducts (po0.001). (B) ELISA using c-Ab was applied to 62 serum samples of obese and 15 plasma samples of non-obese subjects. Obese subjects show significantly higher
levels of HNE–protein adducts (po0.05). Columns represent means7S.D. of triplicate measurement.
605040302010
HNE-adducts (nc-Ab) [pmol/mg]
Fig. 5. Correlation between ELISA methods. Concentrations measured in 77 samples
with the ELISA applying c-Ab or nc-Ab, respectively, correlated significantly
(r¼0.305, po0.01).
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Fig. 7. Dot Blot to determine binding affinity of antibodies to capped HNE–BSA. Dot
Blot was carried out as described in the Materials and Methods section. Antibody
binding to HNE–BSA (5000 pmol/mg) was set to 100%. Histidine side chains were
capped on BSA using DEPC which was then treated with 5000 pmol/mg HNE (His
capped). 50 mg of samples were loaded onto membranes. BSA without HNE-
treatment was loaded as negative control (neg. Con.).
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Fig. 8. Western Blot of HNE–BSA standards and plasma. Quantitative analysis of
Western Blots of HNE-protein adducts in HNE–BSA standards and plasma
(120 pmol/mg with nc-Ab; 1250 pmol/mg with c-Ab) and a representative
Western Blot analysis of HNE–protein adducts. Plasma sample was diluted to
10 mg/ml and 20 mg of protein (standards and plasma) were loaded onto gels.
D. Weber et al. / Redox Biology 1 (2013) 226–233 231specific for HNE-His epitope, we chemically blocked His and
tested – after HNE-treatment – whether the antibodies recognize
the modified protein to the same extent.Dot blot analysis using the nc-Ab confirmed that His capping
reduced the signal to 11.7%, whereas the binding of the c-Ab was
reduced only to 90.9% compared to HNE-BSA without capping
(Fig. 7). The negative control, BSA without HNE added, was
negative for both antibodies, indicating no or very low signal
could be detected when HNE-modified BSA is not present.
D. Weber et al. / Redox Biology 1 (2013) 226–233232Western blot analysis of HNE–BSA standards and plasma sample
We decided to further test the sensitivity of both antibodies in
immunoblots. While both primary antibodies detect the same
band in human plasma samples (molecular weight of approxi-
mately 50 kDa; Fig. 8B), differences in their sensitivity towards
HNE-BSA standards were observed (Fig. 8). Band signal intensity
of standards obtained with the nc-Ab, was many times higher
than for the c-Ab (Fig. 8A).Discussion
The present work compares two antibodies against HNE–
protein adducts in an ELISA method to determine protein-bound
HNE in human plasma and serum. The performance of both
methods was evaluated for linearity, recovery, inter-day and
inter-assay precision, and limit of detection. Regardless which
antibody was used (nc-Ab and/or c-Ab), this method has shown
great linearity (R240.99), in each and repeated measurements.
Recovery for both antibodies, even on its limit of detection was
99.274.5% for nc-Ab and 98.1717.4% for c-Ab, giving the overall
recovery of 98.676.1% for nc-Ab and 103.3718.4% for c-Ab,
respectively. Inter-day and especially inter-assay precision,
expressed as coefficient of variance (CV) does not exceed 22%,
for both tested antibodies, which are acceptable criteria for ELISA
with biological samples. Therefore, the main conclusion of this
validation is that the method is working for both antibodies used
and it allows the measurement of HNE-protein adducts in human
plasma/serum.
Furthermore, the results obtained with each antibody in 77
samples (62 obese serum samples and plasma samples of 15
controls) show significant positive correlation with MDA, another
lipid peroxidation marker. Correlation between both ELISAs
(nc-Ab vs. c-Ab) was also positive and significant. The results
from the different methods demonstrate the same tendency,
which is a significant increase of HNE–protein adducts in the
obese group. The correlation between obesity, oxidative stress
and lipid peroxidation has already been well established. One
characteristic feature of obesity is low-grade chronic inflamma-
tion of the adipose tissue with its concomitant oxidative stress
[21]. Authors have reported increased oxidative stress and lipid
peroxidation (MDA levels) are related to fat accumulation and
BMI [22–24]. Many studies have demonstrated some role of HNE
in the pathophysiology of obesity [25–28]. Since our results are in
accordance with previous findings, we conclude that both meth-
ods are working but surprisingly, differences in quantification
range of HNE–protein adducts in plasma/serum between both
ELISAs were observed (nc-Ab:low; c-Ab:high).
When analyzing human blood samples it is important to take
into account the specimen, the kind of sample, e.g. serum, EDTA-
plasma, heparin or citrate plasma. The main difference between
serum and plasma lies in clotting factors which are still present in
plasma due to the addition of anticoagulants like EDTA, heparin or
citrate. In serum, these clotting factors are consumed and there-
fore missing. For clinical trials, making sure that the specimen
within the cohort is of the same kind is essential.
However, in a recent review, Giustarini et al. have demonstrated
the effect of blood anticoagulation on MDA levels analyzed by
GC–MS/MS in a group of 18 healthy young female volunteers [29].
Blood was taken using EDTA, lithium heparin, or serum monovettes.
Concentrations of MDA in serum and heparin plasma were
in the same range. Furthermore, a positive significant correlation
(correlation coefficient 0.96) for MDA between serum and heparin
plasma samples was reported (n¼14) [30]. For reasons of sample
availability, we compared serum samples with heparinized plasmasamples of controls. Samples were diluted to the same protein
concentration (10 mg/ml) to generally compare the amount of HNE
bound to total proteins and to overcome the effect of clotting factors
present/missing.
Both used antibodies are stated to be specific for the HNE-His
epitope, however this seems to be unlikely given the different
absolute levels. Therefore, experiments where BSA was treated in
order to cap His prior to addition of HNE were undertaken. Thus
prepared samples were further analyzed by dot blot. The dot blots
confirm that the nc-Ab preferentially, and the c-Ab only partly
recognizes the HNE-His epitope.
However, differences were observed when His was capped.
While nc-Ab exhibits only slight binding (11.771.6%), results
obtained with c-Ab display rather high binding (90.972.2%)
compared to binding towards non-capped BSA, giving evidence
that this latter antibody is not specific to the HNE-His epitope but
may also recognize HNE bound to Cys and Lys, and possibly even
other amino acid residues like tyrosine, serine, arginine, proline,
proposing one of possible explanations [14,31,32].
The antigenic sites recognized by the two antibodies on
modified albumin are apparently markedly different. However,
both antibodies were produced with the use of keyhole limpet
hemocyanin (KLH) modified by HNE and there were small
differences in the ratio of HNE:immunogen used (2000 nmol/mg
HNE-KLH for nc-Ab [33] and 1740 nmol/mg HNE-KLH for c-Ab
[34]), therefore neither the degree of modification of the immu-
nogen itself nor the antigene used can be the reason for the diffe-
rence seen in affinity and sensitivity of antibodies.
Furthermore, we tested whether there were any qualitative
differences between the two antibodies in the nature of plasma or
serum proteins detected. Both antibodies specifically recognize
preferentially one band in HNE-BSA standards and one in plasma
and serum, as seen in Western Blots. This supports our intention
to use BSA as a model protein, because albumin is one of the most
abundant plasma proteins and is modified by HNE.
Because of the different results obtained, we suggest using
the terms HNE-His-ELISA for the nc-Ab, and HNE-protein adduct
ELISA for the c-Ab, respectively.
In the present work we show elevated levels of HNE–protein
adducts and MDA in morbidly obese subjects for each of
the applied primary antibodies, showing excellent correlation
between the MDA levels and the HNE-His-ELISA, thus confirming
the data obtained on human UV irradiated plasma and comple-
mentarities of the two methods (the MDA HPLC and the HNE-His-
ELISA) [35].
As we were able to show, the non-commercial anti-HNE
antibody appears to recognize only histidine epitopes, while the
c-Ab recognized various amino acid residues. This fact likely
explains why the detection of HNE adducts with the commercial
Ab leads to quantitative values of about 40-fold higher than those
achieved when using the non-commercial Ab and showed
less statistical power (results reported in Fig. 4). Furthermore,
besides the net difference in specificity, the two antibodies
showed a quite different sensitivity as well (data reported in
Fig. 8). As evidently shown, the nc-Ab is more specific and also
more sensitive than the c-Ab. Both antibodies definitely do not
measure the same epitopes, clearly indicating the requirement of
testing the epitopes before using the antibody. We postulate that
the c-Ab also measures other HNE adducts than those to histidine.
This accounts for the 40-fold difference in absolute concentra-
tions.
In conclusion, oxidative stress or more precisely the level of
oxidative damage to lipids and consequently proteins, as mea-
sured by free MDA and by HNE–protein adducts, was significantly
increased in obese humans if compared to healthy controls.
We are certain that the presented method is suitable for clinical
D. Weber et al. / Redox Biology 1 (2013) 226–233 233application to evaluate lipid peroxidation in human serum or
plasma. Since this ELISA is not time-consuming, it has a high
sample throughput and only essential routine equipment is
needed. Therefore, it is an appropriate alternative as well as
complementary method to the HNE-HPLC, which is not only
time-consuming, but also requires costly equipment.Acknowledgments
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